Several new systemic agents, including histone deacetylase inhibitors (HDACis), folate analog metabolic inhibitors, and anti-CD30 antibody–drug conjugate, have been approved for the treatment of initial or relapsed PTCL [4–6]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.